Vaxcyte

Mizuho reiterated a Buy on Vaxcyte with a $163 price target, implying roughly 180% upside. Vaxcyte is conducting an early-stage VAX-A1 trial testing three dose levels versus placebo to assess safety, tolerability and immunogenicity against Group A strep. Positive results could open a new prevention market and lift the stock, while disappointing data would raise concerns and shift focus to larger vaccine rivals such as Pfizer and GSK. The company remains a clinical-stage vaccine developer with lead programs including VAX-24. » More on finance.yahoo.com

Vaxcyte dosed the first participant in the Phase 1 first-in-human trial of VAX-A1, its experimental vaccine against Group A Streptococcus, a disease with no approved vaccine. The randomized, placebo-controlled study will enroll 80 healthy adults in Australia and proceed in two stages, with an initial 12-participant safety checkpoint before expansion. Participants will receive two doses about two months apart, with low, mid and high dose cohorts tested and safety and immune responses monitored for six months after the final dose. » More on finance.yahoo.com

Vaxcyte announced dosing of the first participant in a first-in-human Phase 1 trial of VAX-A1, a prophylactic vaccine candidate against Group A Streptococcus in healthy adults 18–40. The randomized, double-blind, placebo-controlled, dose-escalation two-stage study will assess safety and tolerability as the primary objective and initial immunogenicity as a secondary objective. Stage 1 will enroll about 12 adults across three dose levels versus placebo, with Stage 2 enrolling about 68 adults after DSMB approval; topline data are expected in the second half of 2027. » More on finance.yahoo.com